PMID- 32486914 OWN - NLM STAT- MEDLINE DCOM- 20210923 LR - 20210923 IS - 1937-335X (Electronic) IS - 1937-3341 (Linking) VI - 26 IP - 21-22 DP - 2020 Nov TI - Acellular Human Amniotic Membrane Scaffold with 15d-PGJ(2) Nanoparticles in Postinfarct Rat Model. PG - 1128-1137 LID - 10.1089/ten.TEA.2019.0340 [doi] AB - The difficulty in the regeneration of cardiomyocytes after myocardial infarction is a major cause of heart failure. Together, the amniotic membrane and 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ(2)) can help in the recovery of cardiomyocyte, as they present many growth factors and anti-inflammatory effect, respectively. The objective of this study is to compare the efficacy of Human Decellularized Amniotic Membrane Scaffold (AHAS) loaded with 15d-PGJ(2) in improving ventricular function in a rat model of postinfarct ventricular dysfunction. Myocardial infarction was induced in 24 rats by left coronary occlusion. After a week, the animals were subjected to echocardiography for evaluation of left ventricle ejection fraction (LVEF), left ventricle end diastolic volume (LVEDV), and left ventricle end systolic volume (LVESV). Animals with ejection fraction <40% were included in the study and were randomized into three groups: control (n = 8), AHAS (n = 8) and AHAS +15d-PGJ(2) (n = 8). In the AHAS group only the membrane was implanted, whereas in the AHAS +15d-PGJ(2) the membrane +15d-PGJ(2) was implanted on myocardial infarction. Echocardiographic evaluation was performed after 1 month. For histological analysis, heart tissue was stained with Gomori trichome, Sirius Red, the antibody against CD31 and connexin 43 (Cx43). There were no significant differences in the baseline LVEF, LVEDV, and LVESV in all groups. After 1 month, ejection fraction decreased in the control group but increased in the AHAS group and in the AHAS +15d-PGJ(2) group in comparison with the control group. The LVEDV and LVESV in the AHAS and AHAS +15d-PGJ(2) groups decreased compared with the control group, featuring a ventricular antiremodeling effect. Histopathology of the infarcted area identified the reduction of infarct size and collagen type 1 in the AHAS and AHAS +15d-PGJ(2) groups. New blood vessels and cardiomyocytes have been identified in an infarcted area by CD31 and Cx43. AHAS +15d-PGJ(2) provided an increase in the ejection fraction and prevented ventricular dilation in this postinfarction ventricular dysfunction model. Impact Statement Our study demonstrated reduction of myocardial fibrosis, proliferation of cardiomyocytes and increase in ejection fraction in rats after experimental acellular amniotic membrane scaffold (AHAS) carrying nanoparticles of 15d-PGJ2 scaffold engraftment in infarcted myocardium. AHAS grafts facilitated colonization of fibrotic myocardium regions with new contractile cells, in addition to preventing reduction of left ventricle wall thickness. This contribution is theoretically and practically relevant as current literature describes experimental studies performed on cardiac ischemic models which present conflicting results concerning cell types used in a research model. FAU - Francisco, Julio Cesar AU - Francisco JC AD - Laboratory of Cardiovascular Surgery and Pathophysiology of Circulation, Department of Cardiopneumology, Heart Institute (Incor), Sao Paulo University Medical School, Sao Paulo, Brazil. AD - Positivo University (UP), R. Professor Pedro Viriato Parigot de Souza, Curitiba, Brazil. FAU - Uemura, Laercio AU - Uemura L AD - Experimental Laboratory of Institute of Biological and Health Sciences of Pontifical Catholic University of Parana (PUCPR), Curitiba, Brazil. FAU - Simeoni, Rossana Baggio AU - Simeoni RB AD - Experimental Laboratory of Institute of Biological and Health Sciences of Pontifical Catholic University of Parana (PUCPR), Curitiba, Brazil. AD - The Parana Institute of Technology-TECPAR, Curitiba, Brazil. FAU - da Cunha, Ricardo Correa AU - da Cunha RC AD - Positivo University (UP), R. Professor Pedro Viriato Parigot de Souza, Curitiba, Brazil. FAU - Mogharbel, Bassam Felipe AU - Mogharbel BF AD - Cell Therapy and Biotechnology in Regenerative Medicine Department, The Pele Pequeno Principe Institute, Child and Adolescent Health Research and Pequeno Principe Faculty, Curitiba, Brazil. Sao Leopoldo Mandic Institute and Researcher Center, Campinas, Brazil. FAU - Simeoni, Paulo Ricardo Baggio AU - Simeoni PRB AD - Experimental Laboratory of Institute of Biological and Health Sciences of Pontifical Catholic University of Parana (PUCPR), Curitiba, Brazil. FAU - Naves, Guilherme AU - Naves G AD - Experimental Laboratory of Institute of Biological and Health Sciences of Pontifical Catholic University of Parana (PUCPR), Curitiba, Brazil. FAU - Napimoga, Marcelo Henrique AU - Napimoga MH AD - Laboratory of Immunology and Molecular Biology, Sao Leopoldo Mandic Institute and Researcher Center, Campinas, Brazil. FAU - Noronha, Lucia AU - Noronha L AD - Experimental Laboratory of Institute of Biological and Health Sciences of Pontifical Catholic University of Parana (PUCPR), Curitiba, Brazil. FAU - Carvalho, Katherine Athayde Teixeira AU - Carvalho KAT AD - Cell Therapy and Biotechnology in Regenerative Medicine Department, The Pele Pequeno Principe Institute, Child and Adolescent Health Research and Pequeno Principe Faculty, Curitiba, Brazil. Sao Leopoldo Mandic Institute and Researcher Center, Campinas, Brazil. FAU - Moreira, Luiz Felipe Pinho AU - Moreira LFP AD - Laboratory of Cardiovascular Surgery and Pathophysiology of Circulation, Department of Cardiopneumology, Heart Institute (Incor), Sao Paulo University Medical School, Sao Paulo, Brazil. FAU - Guarita-Souza, Luiz Cesar AU - Guarita-Souza LC AD - Experimental Laboratory of Institute of Biological and Health Sciences of Pontifical Catholic University of Parana (PUCPR), Curitiba, Brazil. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200818 PL - United States TA - Tissue Eng Part A JT - Tissue engineering. Part A JID - 101466659 RN - 0 (15-deoxy-delta(12,14)-prostaglandin J2) RN - RXY07S6CZ2 (Prostaglandin D2) SB - IM MH - *Amnion MH - Animals MH - Humans MH - *Myocardial Infarction/therapy MH - Myocytes, Cardiac MH - *Nanoparticles MH - Prostaglandin D2/*analogs & derivatives MH - Rats MH - *Tissue Scaffolds OTO - NOTNLM OT - 15d-PGJ2 OT - PPAR-gamma OT - anti-inflammatory OT - heart OT - myocardial infarction EDAT- 2020/06/04 06:00 MHDA- 2021/09/24 06:00 CRDT- 2020/06/04 06:00 PHST- 2020/06/04 06:00 [pubmed] PHST- 2021/09/24 06:00 [medline] PHST- 2020/06/04 06:00 [entrez] AID - 10.1089/ten.TEA.2019.0340 [doi] PST - ppublish SO - Tissue Eng Part A. 2020 Nov;26(21-22):1128-1137. doi: 10.1089/ten.TEA.2019.0340. Epub 2020 Aug 18.